Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 352 results for depression

  1. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    or increased listening demands) or indirectly via social isolation and depression (which are known be associated with cognitive decline...

    Research recommendation
    Published
    10 December 2018

  2. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729

  3. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

    Technology appraisal guidance
    Published
    24 July 2024
    View recommendations

    Sections for TA988

  4. Rehabilitation after critical illness in adults (QS158)

    This quality standard covers adults with rehabilitation needs as a result of critical illness that required level 2 or level 3 critical care. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS158

  5. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.

    Public health guideline
    Published
    28 May 2014
    View recommendations

    Sections for PH53

  6. Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

    Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.

    Technology appraisal guidance
    Published
    5 October 2022
    View recommendations

    Sections for TA828

  7. Extracranial to intracranial bypass for intracranial atherosclerosis (IPG596)

    Evidence-based recommendations on extracranial to intracranial bypass for intracranial atherosclerosis. This involves joining a blood vessel from outside the skull to one inside the skull to bypass a narrowed or partially blocked vessel.

    Interventional procedures guidance
    Published
    8 November 2017
    View recommendations

    Sections for IPG596

  8. Medicines associated with dependence or withdrawal symptoms. Patient decision aid full version on should I stop my benzodiazepine or z-drug?

    z-drug if: : You are having a mental health crisis, such as mania or severe depression. It's best to treat that before reducing your...

  9. Management of inflammatory arthritis

    ). We have published a guideline on the recognition and management of depression in adults with a chronic physical health problem . We...

  10. Insertion of a magnetic bead band for faecal incontinence (IPG483)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

    Interventional procedures guidance
    Published
    27 March 2014
    View recommendations

    Sections for IPG483

  11. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

    Highly specialised technologies guidance
    Published
    6 July 2022
    View recommendations

    Sections for HST21

  12. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  13. Transcranial magnetic stimulation for severe depression (IPG242)

    This guidance has been updated and replaced by NICE interventional procedure guidance 542.

    Interventional procedures guidance
    Published
    28 November 2007

  14. Supporting adult carers (QS200)

    This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 March 2021
    View quality statements

    Sections for QS200

  15. End of life care for infants, children and young people (QS160)

    This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 September 2017
    View quality statements

    Sections for QS160